ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IMGN
- CUSIP: 45253H10
- Web: www.immunogen.com
Capitalization:- Market Cap: $735.04 million
- Outstanding Shares: 89,597,000
Average Prices:- 50 Day Moving Avg: $6.59
- 200 Day Moving Avg: $5.25
- 52 Week Range: $1.51 - $8.84
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.65
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $83.41 million
- Price / Sales: 7.20
- Book Value: ($1.93) per share
- Price / Book: -3.47
Profitability:- EBIDTA: ($69,450,000.00)
- Net Margins: -117.80%
- Return on Assets: -52.58%
Debt:- Debt-to-Equity Ratio: -0.56%
- Current Ratio: 2.40%
- Quick Ratio: 2.34%
Misc:- Average Volume: 3.76 million shs.
- Beta: 2.37
- Short Ratio: 5.29
Frequently Asked Questions for ImmunoGen (NASDAQ:IMGN)
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, July, 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.07. The firm earned $39.02 million during the quarter, compared to analyst estimates of $30.59 million. The company's quarterly revenue was up 426.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. View ImmunoGen's Earnings History.
Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?
8 equities research analysts have issued 12-month price targets for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they anticipate ImmunoGen's share price to reach $8.05 in the next twelve months. View Analyst Ratings for ImmunoGen.
What are analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. Cantor Fitzgerald analysts commented, "IMGN’s speed to market strategy with mirvetuximab soravtansine is intended to advance the drug through the regulatory process by the end of 2020 (FORWARD I), and it is on track." (9/25/2017)
- 2. Cowen and Company analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
- 3. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Momenta Pharmaceuticals (MNTA), Esperion Therapeutics (ESPR), Genus plc (GNS), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA) and Spectrum Pharmaceuticals (SPPI).
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Stephen C. McCluski, Independent Chairman of the Board
- Mark J. Enyedy, President, Chief Executive Officer, Director
- David B. Johnston PhD, Chief Financial Officer, Executive Vice President
- Ellie Harrison, Chief Human Resource Officer, Vice President
- Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
- John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
- Craig Barrows, Vice President, General Counsel, Secretary
- Peter J. Williams, Vice President - Business Development
- Mark A. Goldberg M.D., Independent Director
- Dean Jonathan Mitchell, Independent Director
Who owns ImmunoGen stock?
ImmunoGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.43%), Redmile Group LLC (5.82%),
POLYGON MANAGEMENT LTD.
(5.20%), Vanguard Group Inc. (4.87%), State Street Corp (4.62%) and Wells Fargo & Company MN (1.81%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.
Who sold ImmunoGen stock? Who is selling ImmunoGen stock?
ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including KBC Group NV, Pinnacle Associates Ltd., Wells Fargo & Company MN, Teachers Advisors LLC, Creative Planning, Swiss National Bank, UBS Asset Management Americas Inc. and Northern Trust Corp. View Insider Buying and Selling for ImmunoGen.
Who bought ImmunoGen stock? Who is buying ImmunoGen stock?
ImmunoGen's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Redmile Group LLC, EAM Investors LLC, Candriam Luxembourg S.C.A., Farallon Capital Management LLC, AXA and Paulson & CO. Inc.. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.
How do I buy ImmunoGen stock?
Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of ImmunoGen stock can currently be purchased for approximately $6.70.
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $8.05 (20.15% upside) |
Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/25/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $5.00 | Low |  |
| 8/30/2017 | Canaccord Genuity | Reiterated Rating | Buy | $8.00 -> $10.00 | Medium | |
| 8/29/2017 | Cowen and Company | Reiterated Rating | Hold | | High | |
| 8/29/2017 | Leerink Swann | Reiterated Rating | Outperform -> Buy | | High | |
| 8/7/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $9.00 | Medium | |
| 7/6/2017 | Royal Bank Of Canada | Upgrade | Sector Perform -> Outperform | $5.00 -> $12.00 | High | |
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | High | |
| 3/1/2017 | Morgan Stanley | Lower Price Target | Underweight | $2.50 -> $1.30 | N/A | |
| 8/5/2016 | J P Morgan Chase & Co | Set Price Target | Hold | $9.00 -> $5.00 | N/A | |
| 11/10/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $24.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for ImmunoGen (NASDAQ:IMGN)Earnings History by Quarter for ImmunoGen (NASDAQ IMGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/28/2017 | Q2 2017 | ($0.17) | ($0.10) | $30.59 million | $39.02 million | View | N/A | |
| 5/5/2017 | 3/31/2017 | ($0.36) | ($0.20) | $16.16 million | $28.70 million | View | N/A | |
| 2/17/2017 | Q2 2017 | ($0.39) | ($0.39) | $16.28 million | $13.85 million | View | Listen | |
| 10/28/2016 | Q117 | ($0.38) | ($0.51) | $21.12 million | $7.66 million | View | Listen | |
| 8/4/2016 | Q416 | ($0.39) | ($0.51) | $17.11 million | $7.41 million | View | Listen | |
| 4/29/2016 | Q316 | ($0.31) | ($0.37) | $23.02 million | $19.71 million | View | Listen | |
| 1/29/2016 | Q216 | ($0.36) | ($0.38) | $19.54 million | $18.03 million | View | Listen | |
| 10/27/2015 | Q116 | ($0.35) | ($0.39) | $15.84 million | $14.90 million | View | Listen | |
| 7/31/2015 | Q415 | ($0.34) | ($0.35) | $15.42 million | $12.61 million | View | Listen | |
| 4/24/2015 | Q315 | ($0.25) | ($0.25) | $20.95 million | $11.40 million | View | Listen | |
| 1/30/2015 | Q215 | ($0.06) | $0.16 | $37.30 million | $48.30 million | View | Listen | |
| 10/24/2014 | Q115 | ($0.14) | ($0.26) | $21.80 million | $13.20 million | View | Listen | |
| 8/1/2014 | Q414 | ($0.36) | ($0.31) | $9.72 million | $5.74 million | View | N/A | |
| 4/25/2014 | Q314 | ($0.27) | ($0.44) | $13.28 million | $6.90 million | View | N/A | |
| 1/31/2014 | Q214 | ($0.18) | ($0.29) | $18.16 million | $30.10 million | View | Listen | |
| 10/25/2013 | Q114 | ($0.23) | ($0.13) | $12.10 million | $17.20 million | View | N/A | |
| 8/2/2013 | Q4 2013 | ($0.30) | ($0.26) | $3.44 million | $3.83 million | View | N/A | |
| 4/26/2013 | Q3 2013 | ($0.15) | ($0.02) | $11.94 million | $25.00 million | View | N/A | |
| 1/25/2013 | Q2 2013 | ($0.25) | ($0.29) | $6.02 million | $2.60 million | View | N/A | |
| 10/26/2012 | Q113 | ($0.25) | ($0.30) | $4.10 million | $4.10 million | View | N/A | |
| 8/3/2012 | | ($0.30) | ($0.29) | | | View | N/A | |
| 4/27/2012 | | ($0.26) | ($0.24) | | | View | N/A | |
| 1/27/2012 | | ($0.22) | ($0.17) | | | View | N/A | |
| 10/27/2011 | | ($0.22) | ($0.26) | | | View | N/A | |
| 8/3/2011 | | ($0.24) | ($0.23) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ImmunoGen (NASDAQ:IMGN)2017 EPS Consensus Estimate: ($1.18)
2018 EPS Consensus Estimate: ($1.53)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.33) | ($0.33) | ($0.33) |
| Q2 2017 | 3 | ($0.35) | $0.17 | ($0.07) |
| Q3 2017 | 3 | ($0.46) | ($0.37) | ($0.41) |
| Q4 2017 | 2 | ($0.40) | ($0.34) | ($0.37) |
| Q1 2018 | 1 | ($0.41) | ($0.41) | ($0.41) |
| Q2 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q3 2018 | 1 | ($0.37) | ($0.37) | ($0.37) |
| Q4 2018 | 1 | ($0.38) | ($0.38) | ($0.38) |
(Data provided by Zacks Investment Research)
Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ImmunoGen (NASDAQ:IMGN)Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 67.57%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/15/2017 | Craig Barrows | VP | Sell | 37,050 | $6.81 | $252,310.50 | |
| 9/13/2017 | Craig Barrows | VP | Sell | 14,600 | $6.95 | $101,470.00 | |
| 12/15/2016 | Mark Alan Goldberg | Director | Buy | 20,000 | $1.80 | $36,000.00 | |
| 11/8/2016 | Mark J Enyedy | CEO | Buy | 25,000 | $1.83 | $45,750.00 | |
| 11/2/2016 | Craig Barrows | Insider | Buy | 10,000 | $1.71 | $17,100.00 | |
| 11/2/2016 | Richard J Gregory | VP | Buy | 16,600 | $1.78 | $29,548.00 | |
| 2/1/2016 | John Lambert | EVP | Sell | 3,889 | $8.22 | $31,967.58 | |
| 1/8/2016 | Richard J Gregory | VP | Sell | 2,369 | $11.10 | $26,295.90 | |
| 1/4/2016 | Daniel M. Junius | CEO | Sell | 5,416 | $13.17 | $71,328.72 | |
| 1/4/2016 | John Lambert | EVP | Sell | 3,889 | $13.20 | $51,334.80 | |
| 12/1/2015 | Daniel M. Junius | CEO | Sell | 5,416 | $13.11 | $71,003.76 | |
| 12/1/2015 | John Lambert | EVP | Sell | 3,889 | $13.11 | $50,984.79 | |
| 11/27/2015 | Charles Q Morris | VP | Sell | 5,170 | $14.00 | $72,380.00 | |
| 11/17/2015 | Dean J Mitchell | Director | Buy | 10,000 | $12.51 | $125,100.00 | |
| 11/2/2015 | Daniel M. Junius | CEO | Sell | 5,497 | $12.00 | $65,964.00 | |
| 11/2/2015 | John Lambert | EVP | Sell | 3,889 | $11.73 | $45,617.97 | |
| 10/29/2015 | Daniel M. Junius | CEO | Sell | 5,335 | $12.01 | $64,073.35 | |
| 10/1/2015 | John Lambert | EVP | Sell | 3,889 | $9.55 | $37,139.95 | |
| 9/17/2015 | David Brannon Johnston | CFO | Sell | 5,000 | $15.00 | $75,000.00 | |
| 9/1/2015 | Daniel M. Junius | CEO | Sell | 5,416 | $13.15 | $71,220.40 | |
| 9/1/2015 | John Lambert | EVP | Sell | 3,889 | $13.16 | $51,179.24 | |
| 7/1/2015 | Daniel M Junius | CEO | Sell | 5,416 | $14.34 | $77,665.44 | |
| 7/1/2015 | John Lambert | EVP | Sell | 3,888 | $14.34 | $55,753.92 | |
| 6/15/2015 | Nicole Onetto | Director | Sell | 3,211 | $13.86 | $44,504.46 | |
| 6/1/2015 | John Lambert | EVP | Sell | 15,000 | $11.78 | $176,700.00 | |
| 5/7/2015 | Daniel M Junius | CEO | Sell | 1,215 | $8.02 | $9,744.30 | |
| 5/1/2015 | John Lambert | EVP | Sell | 10,000 | $8.32 | $83,200.00 | |
| 11/28/2014 | Charles Q Morris | VP | Sell | 5,240 | $10.40 | $54,496.00 | |
| 3/17/2014 | Daniel Junius | CEO | Sell | 15,000 | $16.40 | $246,000.00 | |
| 2/26/2014 | Charles Morris | VP | Sell | 6,936 | $17.35 | $120,339.60 | |
| 2/20/2014 | Charles Morris | VP | Sell | 13,672 | $17.10 | $233,791.20 | |
| 2/18/2014 | Daniel Junius | CEO | Sell | 15,000 | $16.26 | $243,900.00 | |
| 2/3/2014 | John Lambert | EVP | Sell | 4,375 | $14.90 | $65,187.50 | |
| 1/22/2014 | Charles Morris | VP | Sell | 7,138 | $17.00 | $121,346.00 | |
| 1/10/2014 | Theresa Wingrove | VP | Sell | 6,250 | $15.04 | $94,000.00 | |
| 1/2/2014 | John Lambert | EVP | Sell | 4,375 | $14.53 | $63,568.75 | |
| 12/10/2013 | Daniel Junius | CEO | Sell | 15,000 | $15.11 | $226,650.00 | |
| 12/2/2013 | John Lambert | EVP | Sell | 4,375 | $14.70 | $64,312.50 | |
| 11/26/2013 | Charles Morris | VP | Sell | 12,500 | $13.75 | $171,875.00 | |
| 11/1/2013 | John Lambert | EVP | Sell | 4,375 | $16.41 | $71,793.75 | |
| 9/10/2013 | Gregory D Perry | CFO | Sell | 18,337 | $17.82 | $326,765.34 | |
| 9/3/2013 | Daniel Junius | CEO | Sell | 16,667 | $16.43 | $273,838.81 | |
| 9/3/2013 | John Lambert | EVP | Sell | 4,375 | $16.45 | $71,968.75 | |
| 8/1/2013 | Daniel M Junius | CEO | Sell | 16,667 | $19.21 | $320,173.07 | |
| 8/1/2013 | John Lambert | EVP | Sell | 4,375 | $19.21 | $84,043.75 | |
| 7/11/2013 | James J O'leary | VP | Sell | 35,000 | $19.02 | $665,700.00 | |
| 7/3/2013 | Daniel M Junius | CEO | Sell | 16,667 | $17.31 | $288,505.77 | |
| 7/1/2013 | John Lambert | EVP | Sell | 4,375 | $16.80 | $73,500.00 | |
| 6/3/2013 | John Lambert | EVP | Sell | 11,250 | $17.20 | $193,500.00 | |
| 5/24/2013 | James J O'leary | VP | Sell | 28,900 | $18.11 | $523,379.00 | |
| 5/1/2013 | John Lambert | EVP | Sell | 11,250 | $15.56 | $175,050.00 | |
| 4/11/2013 | James J O'leary | VP | Sell | 31,100 | $17.37 | $540,207.00 | |
| 11/8/2012 | Mark Alan Goldberg | Director | Buy | 3,000 | $11.27 | $33,810.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ImmunoGen (NASDAQ:IMGN)
Latest Headlines for ImmunoGen (NASDAQ:IMGN)
| Source: |
|
| Date | Headline |
|---|
 | Cantor Fitzgerald Reaffirms "Hold" Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - September 25 at 6:38 PM |
 | ImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : September 25, 2017
finance.yahoo.com - September 25 at 6:24 PM |
| ImmunoGen, Inc. (IMGN) Downgraded by ValuEngine
www.americanbankingnews.com - September 23 at 8:32 PM |
| ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : September 22, 2017
finance.yahoo.com - September 22 at 1:57 PM |
| Analyzing ImmunoGen (IMGN) and Heron Therapeutics (HRTX)
www.americanbankingnews.com - September 22 at 4:34 AM |
| Analysts Expect ImmunoGen, Inc. (IMGN) Will Post Quarterly Sales of $23.69 Million
www.americanbankingnews.com - September 21 at 7:04 AM |
| ImmunoGen Inc (IMGN): Risks You Need To Consider Before Buying
finance.yahoo.com - September 19 at 12:18 AM |
| Is ImmunoGen Running Out of Steam, or Taking a Breather?
finance.yahoo.com - September 16 at 7:03 PM |
| ImmunoGen, Inc. (IMGN) VP Sells $101,470.00 in Stock
www.americanbankingnews.com - September 15 at 8:02 PM |
| ImmunoGen, Inc. (IMGN) VP Craig Barrows Sells 37,050 Shares
www.americanbankingnews.com - September 15 at 4:30 PM |
 | Why Shares of ImmunoGen, Inc. Sank Today
www.fool.com - September 12 at 6:53 PM |
 | ImmunoGen (IMGN) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 12 at 1:39 AM |
| Behind Jazz’s Strategic Collaboration with ImmunoGen
finance.yahoo.com - September 7 at 8:04 PM |
| ImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 6 at 10:42 PM |
| ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
finance.yahoo.com - September 6 at 6:20 AM |
| ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
finance.yahoo.com - September 1 at 8:14 PM |
 | ImmunoGen (IMGN) Up 17.7% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - September 1 at 12:52 AM |
| -$0.30 Earnings Per Share Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - August 31 at 10:30 PM |
| Today's Research Reports on Stocks to Watch: ImmunoGen, Inc. and Acorda Therapeutics Inc.
finance.yahoo.com - August 31 at 7:49 PM |
| ImmunoGen (IMGN) Up 17.7% Since Earnings Report: Can It Continue?
finance.yahoo.com - August 31 at 7:49 PM |
| ETFs with exposure to ImmunoGen, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 7:49 PM |
| Leerink Swann Analysts Raise Earnings Estimates for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - August 31 at 9:24 AM |
| Immunogen Inks Jazz Deal: Moves To Push Tech To Limits - Seeking Alpha
seekingalpha.com - August 31 at 6:11 AM |
| Why Investors Bid Immunogen Inc. Up Almost 12% Today
www.fool.com - August 30 at 6:25 PM |
| ImmunoGen, Inc. (IMGN) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - August 30 at 11:36 AM |
 | ImmunoGen Higher After Announcing Strategic Collaboration With Jazz Pharma
www.benzinga.com - August 30 at 2:09 AM |
 | ACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR
www.rttnews.com - August 30 at 2:09 AM |
| Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products
finance.yahoo.com - August 30 at 2:09 AM |
| Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers
finance.yahoo.com - August 30 at 2:08 AM |
| ImmunoGen and Jazz Enter Into Global Collaboration
finance.yahoo.com - August 30 at 2:08 AM |
| ImmunoGen, Inc. (IMGN) Receives Hold Rating from Cowen and Company
www.americanbankingnews.com - August 29 at 9:28 PM |
| Leerink Swann Reiterates Positive Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - August 29 at 4:06 PM |
| ImmunoGen, Inc. (IMGN) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - August 26 at 4:22 PM |
| ImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 6:13 AM |
| Financial Contrast: Agenus (AGEN) and ImmunoGen (IMGN)
www.americanbankingnews.com - August 22 at 8:26 PM |
| ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : August 16, 2017
finance.yahoo.com - August 16 at 7:49 PM |
| ImmunoGen, Partnerships, Analyst Targets, Pipeline, and Guidance
finance.yahoo.com - August 16 at 1:13 AM |
| Zacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) Will Announce Quarterly Sales of $23.69 Million
www.americanbankingnews.com - August 15 at 7:40 AM |
| Brokerages Expect ImmunoGen, Inc. (NASDAQ:IMGN) to Announce -$0.27 EPS
www.americanbankingnews.com - August 13 at 10:28 AM |
| ImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 12 at 10:50 PM |
 | Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma
www.bizjournals.com - August 11 at 11:08 PM |
| ImmunoGen (IMGN) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 11:08 PM |
| Jefferies Group LLC Reaffirms "Buy" Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - August 7 at 10:14 AM |
| ImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : August 5, 2017
finance.yahoo.com - August 5 at 1:04 AM |
| ImmunoGen, Inc. (IMGN) to Post FY2017 Earnings of ($0.84) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - August 3 at 9:52 AM |
| Here's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
finance.yahoo.com - August 2 at 11:22 PM |
| Here's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
www.fool.com - August 2 at 4:36 PM |
| ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
finance.yahoo.com - August 1 at 8:26 PM |
| ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down - Motley Fool
www.fool.com - August 1 at 5:15 AM |
| ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down
www.fool.com - July 31 at 4:28 PM |
ImmunoGen (IMGN) Chart for Tuesday, September, 26, 2017
